SCHEMBL2909470

SCHEMBL2909470

ONC12CCC(CC1)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3955625 0.91
SCHEMBL17632874 0.82
SCHEMBL1808281 0.77 GRIN2D (0.33)
SCHEMBL16039854 0.76
SCHEMBL15022961 0.72
SCHEMBL3068816 0.72 EPHX2 (0.60)
SCHEMBL3082239 0.72 EPHX2 (0.60)
SCHEMBL3072038 0.72 EPHX2 (0.33)
SCHEMBL3071718 0.72 EPHX2 (0.43)
SCHEMBL3079023 0.72 EPHX2 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217597-A1 QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE COMENTIS, INC. (US) 2010-08-18 EP disclosed
WO-2009046025-A1 QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE COMENTIS, INC. (US) 2009-04-09 WO disclosed
EP-1028961-A1 PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS SMITHKLINE BEECHAM PLC (GB) 2000-08-23 EP disclosed
WO-1999021855-A1 PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS SMITHKLINE BEECHAM P.L.C. (GB) 1999-05-06 WO disclosed
US-3939162-A Anthrapyrimidine dyes BASF AKTIENGESELLSCHAFT (DT) 1976-02-17 US disclosed